EMA Issues Guidance on Patient-Reported Outcomes in Oncology Studies


From DCAT Value Chain Insights (VCI)

By Regulatory News posted 04-26-2016 14:17

  

The European Medicines Agency (EMA) has published new guidance on the use of patient-reported outcome (PRO) measures in oncology studies. The new guidance is an appendix to the guideline on the evaluation of anticancer medicinal products in man, which was last revised in July 2013.

The guidance document, issued by the Committee for Medicinal Products for Human Use (CHMP) and its Oncology Working Party (ONCWP), describes the use of PROs and health-related quality of life (HRQL) measures in clinical studies. It acknowledges the importance of bringing the perspective of patients on their disease and the treatment they receive to the assessment of benefits and risks of cancer medicines. The new guidance outlines principles of scientific best practice rather than prescribing a particular approach to the selection and application of PROs and provides guidance on how patient-reported outcome data should be integrated in oncology clinical trials.

The new guidance provides:recommendations for the incorporation of PROs and HRQL in the clinical development of anticancer medicines and advice on appropriate design, conduct and analysis of PRO studies. PROs include any data directly reported by a patient that is based on his or her perception of a disease and its treatment. They provide information on a patient’s quality of life (impact on any aspect of daily life and social functioning), symptoms, treatment adherence or satisfaction with care. Quality of life during disease and treatment is a personal perspective and may vary from person to person but is possible to be captured using well established methods. PROs and HRQL measures complement the range of traditional indicators of efficacy of an oncology medicine and can provide information regarding both positive and negative patient experiences.

Source: European Medicines Agency

0 comments
64 views


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription 

Permalink